Quarterly ResultMay 19, 2026, 04:17 PM
Iridex Q1 Revenue $11.8M, Net Loss $0.5M; Affirms 2026 Guidance
AI Summary
Iridex Corporation reported its first-quarter 2026 financial results, with total revenue of $11.8 million, a slight decrease from the prior year, and a net loss of $0.5 million, an improvement from the $1.7 million loss in Q1 2025. The company saw 14% year-over-year growth in Cyclo G6 product family revenue, reaching $3.6 million, while retina product revenue declined due to international supply constraints. Iridex affirmed its full-year 2026 revenue guidance of $51 million to $53 million and expects to generate positive operating cash flow for the fiscal year.
Key Highlights
- Total revenue was $11.8 million, a 1% decrease from $11.9 million in Q1 2025.
- Net loss improved to $0.5 million ($0.03 per share) from $1.7 million ($0.10 per share) in Q1 2025.
- Cyclo G6 product family revenue grew 14% to $3.6 million, selling 15,500 probes.
- Retina product revenue decreased to $5.8 million from $6.6 million in Q1 2025.
- Operating expenses decreased 4% to $5.1 million compared to $5.3 million in Q1 2025.
- Cash and cash equivalents were $4.6 million as of April 4, 2026, a $1.4 million quarterly decrease.
- Reaffirmed 2026 full-year revenue guidance of $51 million to $53 million.
- Expects to generate positive operating cash flow for fiscal year 2026.
Price Impact
More from IRIX